Search

 
About the Program

 

The Lymphoma Research Foundation's (LRF) Caring for the Lymphoma Patient: Nursing Education on Non-Hodgkin Lymphoma continuing education program, as part of LRF's nurse education initiative, provides an opportunity for nurses to learn about recent updates on the treatment of lymphoma and the management of the disease. The goals of the program are to increase the knowledge, skills and performance of nurses and to maximize the quality of care for lymphoma patients.

Additional Information
This program is free for nurses; however, pre-registration is required. Food and refreshments will be provided for all registered participants.

At the end of this activity a participant should be better able to:
  • Explain the basic biology and treatment options for patients diagnosed with lymphoma.
  • Evaluate emerging therapies used to treat T-cell lymphomas and B-cell lymphomas.
  • Manage patient toxicity from adverse events to improve patient quality of life.
  • Advance patient adherence while undergoing oral therapy treatment regimens.
  • Direct patients with lymphoma and their caregivers to available resources and support offered by the Lymphoma Research Foundation.
Sponsors:







Accreditation Statement

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. All participants will earn 3.25 contact hours under ANCC criteria for attending the program.

Joint Provider Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation (ANCC) through the joint providership of the University of Nebraska Medical Center College of Nursing Continuing Nursing Education (provider) and Lymphoma Research Foundation.

This activity is supported by educational grants from:

Celgene Corporation, Gilead Sciences, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Seattle Genetics